The Type 1 Diabetes TrialNet Consortium was initiated in 2001 following completion of its predecessor, the Diabetes Prevention Trial-Type 1 (DPT-1). This network consists of 14 US and 4 international clinical sites. In addition, there are more than 200 US affiliate sites which perform subject screening, a Central Coordinating Center, and several TrialNet-associated laboratories. The goals of the TrialNet consortium are to prevent or delay the onset of T1D, to test interventions aimed at decreasing beta cell destruction and/or enhancing beta cell survival in persons with T1D with residual beta cell function, and the performance of mechanistic studies. The University of Minnesota (UMN) has been a DPT-1/TrialNet Clinical Center since the beginning. Throughout this history, UMN has been highly productive and engaged, contributing intellectually to project development and reporting, and actively participating in all aspects of each TrialNet project.
The aims of this renewal grant are to continue the tradition of UMN as a high-quality, high-performing TrialNet Clinical Center in the critical areas of project development, screening, recruitment, treatment, follow-up, and reporting;to increase screening rates for detection of subjects at high risk for development of T1D by further developing and supporting UMN affiliates and by exploring general population screening within new UMN research facilities at the Minnesota State Fair;and to foster collaborations with new T1D researchers in the Upper Midwest region.
Type 1 diabetes imposes a tremendous burden on individuals, families, and society. Preventing or delaying the onset of T1D, the primary focus of TrialNet, would reduce costs to society and the suffering of affected individuals and their family.
|Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92|
|Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:|
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
|Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
Showing the most recent 10 out of 67 publications